In conclusion, we showed that a novel treatment with a combination of LC and NR, but not the mono-treatments, significantly attenuated obesity, fat mass, hepatic steatosis and exerted beneficial effects on metabolic control pathways and upstream regulators (ACOX, SCPAP, SREBF2, PPARGC1B, INSR) in the liver. Here, SREBF2 is linked to Hepatic steatosis.